This time delay is less significant when such an approach is employed to revert long-term on-target/off-tumor toxicities that do not pose an immediate threat to the patient’s life, such as B-cell aplasia in CD19 CAR-treated patients. The gene discussed is CD19; the disease is neoplasm.